DNAGinkgo Bioworks Holdings, Inc.
$11.34-23% 1Y
$11.34
$5.4852 weeks$16.09
What is the market doing?
Mixed
1 good, 1 neutral, 1 without dataNo clear lean: nothing decisive, though in an uptrend.
TrendUptrendderived · Oct 8, 2026
In an uptrend, above its rising 50- and 200-day averages. Price is +35% vs its 200-day average.
Insider conviction−$36K (90 days to Oct 8, 2026)SEC EDGAR · Oct 8, 2026
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How DNA is trading
Ginkgo Bioworks Holdings, Inc. is −23% over the past year while the S&P 500 is +18%: 42 points behind the market.
−23%
1-year return · S&P 500 +18%
- vs 200-day average
- +35%
vs 200-day average · a clear uptrend
- RSI (14)
- 63
RSI (14) · neutral
- Below its 52-week high
- 30%
Below its 52-week high
Details›
- Last close2026-10-08
- $11.34
- 1 monthS&P 500 +1.6%
- +67%
- 1 yearS&P 500 +18%
- −23%
- 5 yearsS&P 500 +86%
- −98%
- vs 50-day average$8.48
- +34%
- 52-week high
- $16.09
- 52-week low
- $5.48
- Annualised volatility
- 102%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$2.7M
| Year | Return |
|---|---|
| 2026 (year to date) | +36% |
| 2025 | −15% |
| 2024 | −85% |
| 2023 | 0.00% |
| 2022 | −80% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | +0.59% |
| Feb | 5 | 1 of 5 | −17% |
| Mar | 5 | 0 of 5 | −17% |
| Apr | 5 | 2 of 5 | +1.6% |
| May | 6 | 3 of 6 | −0.58% |
| Jun | 6 | 4 of 6 | +4.4% |
| Jul | 6 | 4 of 6 | +11% |
| Aug | 6 | 1 of 6 | −14% |
| Sep | 6 | 5 of 6 | +22% |
| Oct | 6 | 1 of 6 | −7.8% |
| Nov | 5 | 1 of 5 | −12% |
| Dec | 5 | 2 of 5 | −2.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.